Abstract
The biological effects of radiation affect both neoplastic and normal tissues. The nature and extent of such effects, however, depend on selected biological parameters (e.g., oxygen supply, cell cycle) and can be modified by chemical agents such as radiosensitizers, radioprotectors and chemotherapeutic agents. A precise control of the mode of action of the radiation is important in order to achieve the maximum effect on tumor tissue, while minimizing the effect on normal tissues. Most of the known and routinely used radiosensitizers are neither selective nor tumor specific. This article reviews a new selective and specific modality that increases the sensitivity of solid tumor tissue, especially of radio resistant, hypoxic tumor cells, to radiation. This modality is currently under early clinical evaluation and encompasses the application of Photofrin II, which is already used as a photosensitizer in photodynamic therapy (PDT) at predetermined times prior to irradiation.
Keywords: Porphyrins, encompasses, photosensitizer, hypoxic, Photofrin
Current Pharmaceutical Design
Title: Porphyrins as Radiosensitizing Agents for Solid Neoplasms
Volume: 9 Issue: 25
Author(s): M. Schaffer, B. Ertl-Wagner, P. M. Schaffer, U. Kulka, A. Hofstetter, E. Duhmke and G. Jori
Affiliation:
Keywords: Porphyrins, encompasses, photosensitizer, hypoxic, Photofrin
Abstract: The biological effects of radiation affect both neoplastic and normal tissues. The nature and extent of such effects, however, depend on selected biological parameters (e.g., oxygen supply, cell cycle) and can be modified by chemical agents such as radiosensitizers, radioprotectors and chemotherapeutic agents. A precise control of the mode of action of the radiation is important in order to achieve the maximum effect on tumor tissue, while minimizing the effect on normal tissues. Most of the known and routinely used radiosensitizers are neither selective nor tumor specific. This article reviews a new selective and specific modality that increases the sensitivity of solid tumor tissue, especially of radio resistant, hypoxic tumor cells, to radiation. This modality is currently under early clinical evaluation and encompasses the application of Photofrin II, which is already used as a photosensitizer in photodynamic therapy (PDT) at predetermined times prior to irradiation.
Export Options
About this article
Cite this article as:
Schaffer M., Ertl-Wagner B., Schaffer M. P., Kulka U., Hofstetter A., Duhmke E. and Jori G., Porphyrins as Radiosensitizing Agents for Solid Neoplasms, Current Pharmaceutical Design 2003; 9 (25) . https://dx.doi.org/10.2174/1381612033454153
DOI https://dx.doi.org/10.2174/1381612033454153 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The HOX Gene Network as a Potential Target for Cancer Therapy
Current Cancer Therapy Reviews Drug Repositioning for Treatment of Movement Disorders: From Serendipity to Rational Discovery Strategies
Current Topics in Medicinal Chemistry Patent Selections
Recent Patents on Biomedical Engineering (Discontinued) P2Y Receptors: Focus on Structural, Pharmacological and Functional Aspects in the Brain
Current Medicinal Chemistry Protein Interaction Networks in Metallo Proteins and Docking Approaches of Metallic Compounds with TIMP and MMP in Control of MAPK Pathway
Letters in Drug Design & Discovery Targeting Stem Cells-Clinical Implications for Cancer Therapy
Current Stem Cell Research & Therapy HspB1 Dynamic Phospho-Oligomeric Structure Dependent Interactome as Cancer Therapeutic Target
Current Molecular Medicine Expression Profiles and Bioinformatics Analysis of Full-length circRNA Isoforms in Gliomas
Current Bioinformatics Recent Development in Targeting PI3K-Akt-mTOR Signaling for Anticancer Therapeutic Strategies
Anti-Cancer Agents in Medicinal Chemistry Neoadjuvant Chemotherapy Before Radical Cystectomy: Why We Must Adhere?
Current Drug Targets Concepts for Nano-delivery of Therapeutic Immunomodulatory Agents
Current Bionanotechnology (Discontinued) Chemokine Receptors as Targets for Cancer Therapy
Current Pharmaceutical Design CXCR4 and Glioblastoma
Anti-Cancer Agents in Medicinal Chemistry PET Imaging in Prostate Cancer: Focus on Prostate-Specific Membrane Antigen
Current Topics in Medicinal Chemistry Drug Design Studies of the Novel Antitumor Targets Carbonic Anhydrase IX and XII
Current Medicinal Chemistry Glyco-Nanomaterials: Translating Insights from the “Sugar-Code” to Biomedical Applications
Current Medicinal Chemistry The Role of Tumor Associated Macrophages (TAMs) in Cancer Progression, Chemoresistance, Angiogenesis and Metastasis - Current Status
Current Medicinal Chemistry Will Medicinal Cannabinoids Prove to be Useful Clinically?
Current Drug Therapy Systemic Treatment of Advanced Biliary Tract Carcinoma: Emerging Roles of Targeted Therapy and Molecular Profiling
Clinical Cancer Drugs Renaissance of the Biologically Active Vitamin A Derivatives: Established and Novel Directed Therapies for Cancer and Chemoprevention
Current Pharmaceutical Design